Revenues up by 24% - earnings performance improves substantially

Kleinostheim, July 21, 2003 - On the basis of preliminary figures, curasan AG (WKN: 549 453), a Prime Standard listed company specialising in regenerative medicine, has continued its positive trend of the two previous quarters by producing a solid performance in the second quarter of 2003. Revenues increased by 24% to EUR 8.8 million (previous year: EUR 7.2 million).The company's accumulated loss was reduced by over 60% year on year to EUR 0.5 million. Calculated on the basis of full-time staff, the Group employed 95 (previous year: 114) people in the period under review.

The business segments Pharmaceuticals and Biomaterials contributed to the increase in sales. Growth in exports was above average in all areas. In a period of just six months, the company matched its entire export sales achieved in the full financial year 2002. Within this context, Eastern Europe and the United States played a prominent role.

In the coming months the synthetic bone regeneration material Cerasorb® is to be developed into a comprehensive product line. On this basis, various fields of application will be covered by tailor-made solutions.

"Alongside our growth in export-related sales, the company's fully booked specialist workshops bear testimony to the sustained nature of our market performance and success. Supported by healthy financial results for the first six months of the financial year, we have built a solid foundation to achieve break-even in 2003 as planned," says Hans Dieter Rössler, CEO of curasan AG.

The full Interim Report for the First Six Months is to be published on 11 August 2003 and will be available on the company website at www.curasan.de (Investor Relations section).

Top of page Print page